Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Histopathology|November 8, 2022
The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnosticsMelvin Kilsdonk, Carlijn Veldman, Stefano Rosati, et al.
International Journal of Molecular Sciences|November 26, 2022
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin LymphomaMyra Langendonk, Nienke A M Smit, Wouter Plattel, et al.
Plos One|February 4, 2014
Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphomaZheng Liang, Arjan Diepstra, Chuanhui Xu, et al.
BMC Cancer|April 2, 2024
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCRYujie Zhong, Geok Wee Tan, Johanna Bult, et al.
British Journal of Haematology|December 18, 2025
Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patientsYujie Zhong, Johanna Bult, Nick Veltmaat, et al.
Haematologica|December 20, 2011
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphomaChuanhui Xu, Wouter Plattel, Anke van den Berg, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2025
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphomaDiana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|May 2, 2017
Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G)Sebastiaan H C Klaassen, Henny H Lemmink, Johan Bijzet, et al.
Blood|May 11, 2022
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort studyMirian Brink, Frederik O Meeuwes, Marjolein W M van der Poel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2023
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin LymphomaMassimo Federico, Catherine Fortpied, Yana Stepanishyna, et al.
Pageof 2